Effect of hepatitis C virus infection on the left ventricular systolic and diastolic functions

Southern Medical Journal

Volumn 104, Issue 8, 2011, Pages 543-546

  Demir, Mehmet ^a   Demir, Canan ^a  

^a Research Hospital   (Turkey)

Author keywords

arrhythmias; cardiomyopathy; heart failure; hepatitis C virus; myocarditis

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEPATITIS C; HUMAN; MALE; P WAVE; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADOLESCENT; ADULT; AGED; ATRIAL FIBRILLATION; DIASTOLE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 80051536672     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31822462e2     Document Type: Article

References (24)

1. Sünbül M. Epidemiology and prevention of hepatitis C virus infection. In: Tabak F, Balk I, Tekeli E, eds. Viral Hepatitis. 1st ed. Istanbul, Turkey. 2007:207-219.
2. Kadiroǧlu AK, Göral V, yit D, et al. The evaluation of the prevalence of extrahepatic findings in chronic hepatitis C virus infection. Turkiye Klin J Med Sci 2005;25:621-626. (Pubitemid 41641114)
3. Demir M, Demir C, Üloay A. Effect of hepatitis C virus infection on the left ventricular hypertrophy. Turkiye Klin J Cardiovasc Sci 2009;21: 315-319.
4. Aygen B. Hepatitis C. Turkiye Klin J Int Med Sci 2006;2:21-33.
5. Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 1998;62: 389-391.
6. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005;96:144-147. (Pubitemid 40209360)
7. Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001;6:159-165. (Pubitemid 32423403)
8. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
9. Lang RM, Bierig M, Devereux RB, et al. Task Force on Chamber Quantification; recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108. (Pubitemid 43257193)
10. Quinones MA, Otto CM, Stoddard M, et al. Recommendations for quantitation of Doppler echocardiography: a report from the Doppler Quantification Task force of the nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-184.
11. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac functionVa study in normals and dilated cardiomyopathy. J Cardiol 1995;26:357-366. (Pubitemid 26011184)
12. Matsumori A. Clinical practice of hepatitis: myocardial diseases, nephritis, and vasculitis associated with hepatitis virus. Arch Intern Med 2001;40:182-184. (Pubitemid 33665251)
13. Matsumori A. Role of hepatitis C virus in cardiomyopathies. Ernst Schering Res Found Workshop 2006:99-120.
14. Tsui J, Whooley M, Monto A, et al. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease. J Card Fail 2009;15:451-456.
15. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995;92:2519-2525.
16. Sato Y, Takatsu Y, Yamada T, et al. Interferon treatment for dilated car-diomyopathy and striated myopathy associated with hepatitis C virus infection. Jpn Circ J 2000;64:321-324.
17. Matsumori A, Ohashi N, Nishio R, et al. Apical hypertrophic cardiomy-opathy and hepatitis C virus infection. Jpn Circ J 1999;63:433-438. (Pubitemid 29272545)
18. Matsumori A, Sasayama S. Newer aspects of pathogenesis of heart failure: hepatitis C virus infection in myocarditis and cardiomyopathy. J Card Fail 1996;2(4 suppl):187-194.
19. Kawai K, Hata K, Kawai H, et al. Pathophysiological characteristics and responsiveness to neurohormonal antagonism in idiopathic dilated car-diomyopathy patients with antihepatitis C virus antibody. Int Heart J 2005;46:407-417.
20. Takeda A, Sakata A, Takeda N. Detection of hepatitis C virus RNA in the hearts of patients with hepatogenic cardiomyopathy. Mol Cell Biochem 1999;195:257-261. (Pubitemid 29259790)
21. Tsuchihara K, Hijikata M, Fukuda K, et al. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999;258:100-107. (Pubitemid 29391785)
22. Frustaci A, Calabrese F, Chimenti C, et al. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 2002;122:1348-1356. (Pubitemid 35339551)
23. Okabe M, Fukuda K, Arakawa K, et al. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 1997;96:22-24. (Pubitemid 27298397)
24. Matsumori A, Matoba Y, Nishio R, et al. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1996;222:678-682. (Pubitemid 26194811)